SRDX vs NVCR vs ATRC vs ANGO vs LAKE

For growth investors, Lakeland Industries, Inc.

(LAKE) is the stronger pick with 34. 1% revenue growth year-over-year, versus -4. 9% for Surmodics, Inc. (SRDX). Analysts rate Surmodics, Inc. (SRDX) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Surmodics, Inc.

(SRDX) delivered a total return of -22. 1%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: ATRC returned +95. 1% versus ANGO's -9. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Surmodics, Inc.

(SRDX) is the lower-risk stock at 0. 48β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 359% more volatile than SRDX relative to the S&P 500. On balance sheet safety, AtriCure, Inc. (ATRC) carries a lower debt/equity ratio of 18% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Lakeland Industries, Inc.

(LAKE) is pulling ahead at 34. 1% versus -4. 9% for Surmodics, Inc. (SRDX). On earnings-per-share growth, the picture is similar: AngioDynamics, Inc. grew EPS 81. 9% year-over-year, compared to -645. 5% for Surmodics, Inc.. Over a 3-year CAGR, ATRC leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AtriCure, Inc.

(ATRC) is the more profitable company, earning -2. 1% net margin versus -20. 8% for NovoCure Limited — meaning it keeps -2. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ATRC leads at -0. 6% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NVCR: 99.

0% to $33. 50.

In this comparison, LAKE (1.

1% yield) pays a dividend. SRDX, NVCR, ATRC, ANGO do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Surmodics, Inc.

(SRDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 48)). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SRDX: +88. 4%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SRDX (Healthcare) and NVCR (Healthcare) and ATRC (Healthcare) and ANGO (Healthcare) and LAKE (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SRDX is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; ATRC is a small-cap quality compounder stock; ANGO is a small-cap quality compounder stock; LAKE is a small-cap high-growth stock. LAKE pays a dividend while SRDX, NVCR, ATRC, ANGO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.